Comparative Pharmacology
Head-to-head clinical analysis: SUMYCIN versus TETRAMED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUMYCIN versus TETRAMED.
SUMYCIN vs TETRAMED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
Tetracycline inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
100 mg orally every 12 hours
None Documented
None Documented
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Terminal elimination half-life is 12–15 hours in adults with normal renal function; in renal impairment (CrCl <30 mL/min), half-life may extend to >30 hours, requiring dose adjustment.
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; minor metabolic clearance accounts for 10%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic